Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)

A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. Allogeneic hematopoietic stem cell transplantation, through its graft-versus-tumor effect, can induce clinical responses and prolonged survival in selected cytokine-refra...

Descripción completa

Detalles Bibliográficos
Autores principales: Bregni, Marco, Ciceri, Fabio, Peccatori, Jacopo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119401/
https://www.ncbi.nlm.nih.gov/pubmed/21716855
_version_ 1782206565310267392
author Bregni, Marco
Ciceri, Fabio
Peccatori, Jacopo
author_facet Bregni, Marco
Ciceri, Fabio
Peccatori, Jacopo
author_sort Bregni, Marco
collection PubMed
description A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. Allogeneic hematopoietic stem cell transplantation, through its graft-versus-tumor effect, can induce clinical responses and prolonged survival in selected cytokine-refractory patients. However, the still relevant transplant-related mortality due to toxicity and graft-versus-host disease is an obstacle to its widespread use.
format Online
Article
Text
id pubmed-3119401
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-31194012011-06-28 Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC) Bregni, Marco Ciceri, Fabio Peccatori, Jacopo J Cancer Short Report A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. Allogeneic hematopoietic stem cell transplantation, through its graft-versus-tumor effect, can induce clinical responses and prolonged survival in selected cytokine-refractory patients. However, the still relevant transplant-related mortality due to toxicity and graft-versus-host disease is an obstacle to its widespread use. Ivyspring International Publisher 2011-06-05 /pmc/articles/PMC3119401/ /pubmed/21716855 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Short Report
Bregni, Marco
Ciceri, Fabio
Peccatori, Jacopo
Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
title Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
title_full Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
title_fullStr Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
title_full_unstemmed Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
title_short Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
title_sort allogeneic stem cell transplantation for metastatic renal cell cancer (rcc)
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119401/
https://www.ncbi.nlm.nih.gov/pubmed/21716855
work_keys_str_mv AT bregnimarco allogeneicstemcelltransplantationformetastaticrenalcellcancerrcc
AT cicerifabio allogeneicstemcelltransplantationformetastaticrenalcellcancerrcc
AT peccatorijacopo allogeneicstemcelltransplantationformetastaticrenalcellcancerrcc

Ejemplares similares